Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort

被引：45

作者：

Kissling, Esther ^{[1
]}

Pozo, Francisco ^{[2
]}

Buda, Silke ^{[3
]}

Vilcu, Ana-Maria ^{[4
]}

Gherasim, Alin ^{[5
,6
]}

Brytting, Mia ^{[7
]}

Domegan, Lisa ^{[8
,9
]}

Gomez, Veronica ^{[10
]}

Meijer, Adam ^{[11
]}

Lazar, Mihaela ^{[12
]}

Vucina, Vesna Visekruna ^{[13
]}

Duerrwald, Ralf ^{[14
]}

van der Werf, Sylvie ^{[15
,16
]}

Larrauri, Amparo ^{[5
,6
]}

Enkirch, Theresa ^{[7
]}

O'Donnell, Joan ^{[8
]}

Guiomar, Raquel ^{[17
]}

Hooiveld, Mariette ^{[18
]}

Petrovic, Goranka ^{[13
]}

Stoian, Elena ^{[12
]}

Penttinen, Pasi ^{[19
]}

Valenciano, Marta ^{[1
]}

Preuss, Ute ^{[3
]}

Tolksdorf, Kristin ^{[3
]}

Biere, Barbara ^{[14
]}

Smallfield, Maria ^{[14
]}

Wedde, Marianne ^{[14
]}

Falchi, Alessandra ^{[20
]}

Masse, Shirley ^{[20
]}

Villechenaud, Natacha ^{[20
]}

Souty, Cecile ^{[21
]}

Blanchon, Thierry ^{[21
]}

Launay, Titouan ^{[21
]}

Enouf, Vincent ^{[15
,22
]}

Behillil, Sylvie ^{[15
,22
]}

Lina, Bruno ^{[23
,24
]}

Valette, Martine ^{[23
]}

Mazagatos, Clara ^{[25
]}

Casas, Inmaculada ^{[2
]}

Garcia Comas, Luis ^{[26
]}

Insua Marisquerena, Maria Esther ^{[26
]}

Carlos Galan, Juan ^{[27
]}

Castilla, Jesus ^{[28
,29
]}

Garcia Cenoz, Manuel ^{[28
,29
]}

Navascues, Ana ^{[30
]}

Quinones Rubio, Carmen ^{[31
]}

Ibanez Perez, Ana Carmen ^{[31
]}

Martinez Ochoa, Eva ^{[31
]}

Blasco, Miriam ^{[32
]}

Gimenez Duran, Jaume ^{[33
]}

机构：

[1] Epiconcept, Dept Epidemiol, Paris, France

[2] Inst Hlth Carlos III, WHO Natl Influenza Ctr, Natl Influenza Reference Lab, Natl Ctr Microbiol, Madrid, Spain

[3] Robert Koch Inst, Dept Infect Dis Epidemiol, Resp Infect Unit, Berlin, Germany

[4] Sorbonne Univ, INSERM, IPLESP, UMRS 1136, Paris, France

[5] Inst Hlth Carlos III, Natl Epidemiol Ctr, Madrid, Spain

[6] Inst Hlth Carlos III, CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain

[7] Publ Hlth Agcy Sweden, Stockholm, Sweden

[8] Hlth Protect Surveillance Ctr, Dublin, Ireland

[9] European Ctr Dis Prevent & Control ECDC, EPIET, Stockholm, Sweden

[10] Inst Nacl Saude Dr Ricardo Jorge, Dept Epidemiol, Lisbon, Portugal

[11] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands

[12] Cantacuzino Natl Mil Med Inst Res & Dev, Bucharest, Romania

[13] Croatian Inst Publ Hlth, Div Epidemiol Communicable Dis, Zagreb, Croatia

[14] Robert Koch Inst, Natl Reference Ctr Influenza, Berlin, Germany

[15] Univ Paris Diderot SPC, Unite Genet Mol Virus ARN, Inst Pasteur, CNRS,UMR3569, Paris, France

[16] Inst Pasteur, WHO Natl Influenza Ctr, CNR Virus Infect Resp, Paris, France

[17] Inst Nacl Saude Dr Ricardo Jorge, Dept Doencas Infeciosas, Lisbon, Portugal

[18] Nivel Netherlands Inst Hlth Serv Res, Utrecht, Netherlands

[19] European Ctr Dis Prevent & Control ECDC, Stockholm, Sweden

[20] Univ Corse, INSERM, Lab Virol, Corte, France

[21] Sorbonne Univ, INSERM, IPLESP, Paris, France

[22] Inst Pasteur, CNR Virus Infect Resp, Paris, France

[23] Grp Hosp Nord HCL, Inst Agents Infect, CNR Virus Infect Resp, Lab Virol, Lyon, France

[24] UCBL, Univ Lyon, Fac Med LYON Est, CIRI,Inserm,U1111,CNRS 5308,ENS,Lab Virpath, Lyon, France

[25] CIBERESP, Inst Hlth Carlos III, Natl Ctr Epidemiol, Madrid, Spain

[26] Comunidad Madrid, Direcc Gen Salud Publ, Madrid, Spain

[27] CIBERESP, Lab Hosp Ramon y Cajal, Madrid, Spain

[28] Inst Salud Publ Navarra IdiSNA, Pamplona, Spain

[29] CIBERESP, Pamplona, Spain

[30] Complejo Hosp Navarra IdiSNA, Pamplona, Spain

[31] Direcc Gen Salud Publ & Consumo La Rioja, La Rioja, Spain

[32] Lab Hosp San Pedro Logrono, Logrono, Spain

[33] Direcc Gen Salud Publ, Serv Epidemiol, Mallorca, Spain

[34] Lab Hosp Son Espases, Mallorca, Spain

[35] Consejeria Bienestar Social & Sanidad, DGSC, Serv Epidemiol, Melilla, Spain

[36] Publ Hlth Agcy Sweden, Stockholm, Sweden

[37] HSE Hlth Protect Surveillance Ctr, Dublin, Ireland

[38] Irish Coll Gen Practitioners, Dublin, Ireland

[39] Univ Coll Dublin, Natl Virus Reference Lab, Dublin, Ireland

[40] Inst Nacl Saude Dr Ricardo Jorge, Dept Infect Dis, Bioinformat Unit, Lisbon, Portugal

[41] Croatian Inst Publ Hlth, Dept Virol, Zagreb, Croatia

[42] Epiconcept, Paris, France

来源：

EUROSURVEILLANCE | 2019年 / 24卷 / 48期

关键词：

HEMAGGLUTININ; SUBSTITUTIONS; MODERATE;

D O I：

10.2807/1560-7917.ES.2019.24.48.1900604

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction: Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe in 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences in vaccine effectiveness (VE). Aim: The I-MOVE multicentre primary care test-negative study assessed 2018/19 influenza A(H3N2) VE by age and genetic subgroups to explore VE by birth cohort. Methods: We measured VE against influenza A(H3N2) and (sub)clades. We stratified VE by usual age groups (0-14, 15-64, >= 65-years). To assess the imprint-regulated effect of vaccine (I-REV) hypothesis, we further stratified the middle-aged group, notably including 32-54-year-olds (1964-86) sharing potential childhood imprinting to serine at haemagglutinin position 159. Results: Influenza A(H3N2) VE among all ages was -1% (95% confidence interval (CI): -24 to 18) and 46% (95% CI: 8-68), -26% (95% CI: -66 to 4) and 20% (95% CI: -20 to 46) among 0-14, 15-64 and >= 65-year-olds, respectively. Among 15-64-year-olds, VE against clades 3C.2a1b and 3C.3a was 15% (95% CI: -34 to 50) and -74% (95% CI: -259 to 16), respectively. VE was -18% (95% CI: -140 to 41), -53% (95% CI: -131 to -2) and -12% (95% CI: -74 to 28) among 15-31-year-olds (1987-2003), 32-54-year-olds (1964-86) and 55-64-year-olds (1954-63), respectively. Discussion: The lowest 2018/19 influenza A(H3N2) VE was against clade 3C.3a and among those born 1964-86, corresponding to the I-REV hypothesis. The low influenza A(H3N2) VE in 15-64-year-olds and the public health impact of the I-REV hypothesis warrant further study.

引用

页码：31 / 42

页数：12

共 34 条

[1]

Advisory Committee on Immunization Practices (ACIP), 2019, AG UPD INFL VACC

[2] Birth Cohort Effects in Influenza Surveillance Data: Evidence That First Influenza Infection Affects Later Influenza-Associated Illness [J].

Budd, Alicia P. ;

Beacham, Lauren ;

Smith, Catherine B. ;

Garten, Rebecca J. ;

Reed, Carrie ;

Kniss, Krista ;

Mustaquim, Desiree ;

Ahmad, Farida B. ;

Cummings, Charisse N. ;

Garg, Shikha ;

Levine, Min Z. ;

Fry, Alicia M. ;

Brammer, Lynnette .

JOURNAL OF INFECTIOUS DISEASES, 2019, 220 (05) :820-829

[3]

Butler D, 2019, NATURE, V572

[4] PREDETERMINATION BY INFECTION AND BY VACCINATION OF ANTIBODY RESPONSE TO INFLUENZA VIRUS VACCINES [J].

DAVENPORT, FM ;

HENNESSY, AV .

JOURNAL OF EXPERIMENTAL MEDICINE, 1957, 106 (06) :835-850

[5]

ECDC, 2019, INFL VIR CHAR SUMM E

[6]

European Centre for Disease Prevention and Control (ECDC), 2016, SEAS INFL VACC ANT E

[7] Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season [J].

Flannery, Brendan ;

Kondor, Rebecca J. Garten ;

Chung, Jessie R. ;

Gaglani, Manjusha ;

Reis, Michael ;

Zimmerman, Richard K. ;

Nowalk, Mary Patricia ;

Jackson, Michael L. ;

Jackson, Lisa A. ;

Monto, Arnold S. ;

Martin, Emily T. ;

Belongia, Edward A. ;

McLean, Huong Q. ;

Kim, Sara S. ;

Blanton, Lenee ;

Kniss, Krista ;

Budd, Alicia P. ;

Brammer, Lynnette ;

Stark, Thomas J. ;

Barnes, John R. ;

Wentworth, David E. ;

Fry, Alicia M. ;

Patel, Manish .

JOURNAL OF INFECTIOUS DISEASES, 2020, 221 (01) :8-15

[8] Back to the Future for Influenza PreimmunityLooking Back at Influenza Virus History to Infer the Outcome of Future Infections [J].

Francis, Magen Ellen ;

King, Morgan Leslie ;

Kelvin, Alyson Ann .

VIRUSES-BASEL, 2019, 11 (02)

[9]

Francis T., 1960, P AM PHIL SOC, V104, P572

[10] Basic principles of test-negative design in evaluating influenza vaccine effectiveness [J].

Fukushima, Wakaba ;

Hirota, Yoshio .

VACCINE, 2017, 35 (36) :4796-4800

← 1 2 3 4 →